Switching from B-cell therapy to ozanimod in MS
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing forms of MS for at least 3 years.
- You have been on a B-cell depleting therapy (like Ocrevus, Rituxan, or Kesimpta) for at least 2 years and had no new MS activity in the last 2 years.
- You had your last infusion of that therapy within 6–12 months, or your last injection within 30–180 days.
- You are 18 or older and able to have a brain MRI without anesthesia (no sedation needed).
- You are not pregnant, not planning pregnancy, and willing to use effective birth control during the study.
- You do not have other serious illnesses like uncontrolled diabetes, heart conditions, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This study follows adults with relapsing multiple sclerosis who are switching from ocrelizumab to ofatumumab (two similar MS medications) to see how their immune system proteins (immunoglobulins) change during the switch. It may help doctors understand if this change improves your immune health while treating MS.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.